Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 9/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2516408 | 0.96 | RAB9A (0.46) | ALDH1A1RAB9AKDM4EMAPTPKM | |
| SCHEMBL12035040 | 0.96 | RAB9A (0.46) | ALDH1A1RAB9AKDM4EMAPTPKM | |
| Trifluoroacetic Acid SCHEMBL2519441 | 0.91 | HIF1A (0.49) | ALDH1A1RAB9AMAPTNPC1IDO1 | |
| Trifluoroacetic Acid SCHEMBL2515038 | 0.90 | IDO1 (0.46) | IDO1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2515043 | 0.90 | IDO1 (0.46) | IDO1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2515010 | 0.90 | FAAH (0.43) | NPC1IDO1PTGDR2HDAC1HIF1A | |
| Trifluoroacetic Acid SCHEMBL2515066 | 0.90 | SLC2A1 (0.49) | NPC1IDO1PTGDR2HDAC1HIF1A | |
| SCHEMBL2516417 | 0.90 | IDO1 (0.43) | RAB9ANPC1IDO1PTGDR2HDAC1 | |
| SCHEMBL2515420 | 0.89 | ALDH1A1 (0.44) | ALDH1A1RAB9AKDM4EMAPTPKM | |
| SCHEMBL2518774 | 0.87 | FAAH (0.45) | RAB9ANPC1IDO1PTGDR2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192868-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190210985-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION | 2019-07-11 | — | — | US | disclosed |
| US-10208002-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180030006-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION | 2018-02-01 | — | — | US | disclosed |
| US-20140377292-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2014-12-25 | — | — | US | disclosed |
| US-8846726-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130123246-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2559690-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | Incyte Corporation (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-1879573-B1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORP (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208002-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | ALDH1A1 902/4885RAB9A 4389/4885KDM4E 421/4885 |
| US-20180030006-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | ALDH1A1 902/4885RAB9A 4389/4885KDM4E 421/4885 |
| US-11192868-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | ALDH1A1 902/4885RAB9A 4389/4885KDM4E 421/4885 |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | ALDH1A1 902/4885RAB9A 4389/4885KDM4E 421/4885 |
| US-20190210985-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | ALDH1A1 902/4885RAB9A 4389/4885KDM4E 421/4885 |
| US-20140377292-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | ALDH1A1 902/4885RAB9A 4389/4885KDM4E 421/4885 |
| US-20130123246-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | ALDH1A1 902/4885RAB9A 4389/4885KDM4E 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.